Drug Profile
Diclofenac injection - IBSA
Alternative Names: Akis; Diclofenac HPBCD; DicloinLatest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator IBSA
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute pain; Back pain; Inflammatory pain; Musculoskeletal pain; Postoperative pain; Renal colic
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in Switzerland (IV, Injection)
- 01 Dec 2015 IBSA Biochemical completes a phase I trial in Pain (In volunteers) in Switzerland (IV) (ISRCTN20012465)
- 01 May 2013 IBSA completes a phase II trial in Postoperative pain following dental surgery in the United Kingdom (NCT01706588)